LY 3076226

Drug Profile

LY 3076226

Alternative Names: LY3076226

Latest Information Update: 28 Oct 2015

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 01 Sep 2015 Phase-I clinical trials in Cancer (Late-stage disease) in USA (IV)
  • 25 Aug 2015 Preclinical trials in Cancer in USA (IV)
  • 25 Aug 2015 Eli Lilly plans a phase I trial for Cancer (Late-stage disease, Metastatic disease) in USA (NCT02529553)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top